The Efficacy and Tolerability of Canagliflozin in Healthy Individual

Completed · Phase 4

Conditions studied: Healthy Aging

In brief

The primary objective is to measure the effects that canagliflozin intervention has on reducing average glucose in healthy individuals. The secondary objective is to assess the tolerability and side effects and urinary glucose excretion following the pulsatile dosing protocol.

Key facts

Study ID

NCT06301529

Run by

AgelessRx

People needed

30

Starts

2024-02-12

Expected to finish

2024-06-29

Last updated by the study team

2024-07-19

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-85
• Any sex
• Any ethnicity
• Interest in taking Canagliflozin
• Approved by the AgelessRx Medical team to take Canagliflozin
• Willing and technically able to use and operate a continuous glucose monitor
• Own a CGM-compatible phone
• Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable
• Adequate cognitive function to be able to give informed consent

You may not qualify if…

• Diabetes of any type
• Taking metformin or any other glucose-lowering medication
• Other diabetes medication
• Active malignancy of any kind
• Clinically relevant renal or kidney disease or dysfunction
• History of eating disorder
• Any diuretic
• Taking any medication, or having any medical condition, that might interfere with the action of canagliflozin or the CGM sensor

Where it is running

• AgelessRx — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.